読み込み中
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
前日終値
$25.79
+$0.53 · +2.10%
時間外
$25.79
$0.00 · 0.00%
10月9日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
日中レンジ
現在 $25.79
52週レンジ
現在 $25.79
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
2
著しい割高
センチメント
62
強気
リスク
42
やや高いリスク
モメンタム
53
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
日中レンジ
現在 $25.79
52週レンジ
現在 $25.79
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.06億 USD | 7630.4万 USD | 7601.2万 USD | 4.12億 USD | 2668万 USD |
| 売上原価 | — | — | 1.43億 USD | — | — |
| 粗利益 | 1.06億 USD | 7630.4万 USD | −6697.7万 USD | 4.12億 USD | 2668万 USD |
| 研究開発 | 1.37億 USD | 1.35億 USD | 1.44億 USD | 2.09億 USD | 2億 USD |
| 販売・一般管理 | 6150万 USD | 6150万 USD | 7040万 USD | 7340万 USD | 4260万 USD |
| 営業費用 | 1.99億 USD | 2.13億 USD | 7107.6万 USD | 2.82億 USD | 2.42億 USD |
| 受取利息 | 1335.4万 USD | 1994.1万 USD | 1970.5万 USD | 359.6万 USD | 196.5万 USD |
| 減価償却費と償却費 | 1111万 USD | 1119.3万 USD | 1730.5万 USD | 1200.4万 USD | 958.3万 USD |
| 営業利益 | −9253.5万 USD | −1.37億 USD | −1.38億 USD | 1.31億 USD | −2.16億 USD |
| 純利益 | −8113万 USD | −1.23億 USD | −1.19億 USD | 1.24億 USD | −2.12億 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$41.40
上昇余地（60.53%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI4436.83万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM3045.93万0.04%782.66億 USD0.19%$278.94+0.49%
iShares Biotechnology ETFIBB1350.25万0.13%102.79億 USD0.44%$206.49+3.00%
iShares Russell 2000 Growth ETFIWO1062.33万0.08%139.72億 USD0.24%$356.78+0.94%
Dimensional - US Small Cap ETFDFAS796.64万0.02%338.69億 USD0.31%$78.35+0.32%
Vanguard Russell 2000 ETFVTWO795.88万0.04%180億 USD0.06%$112.66+0.50%
Vanguard Health Care ETFVHT360.85万0.02%220億 USD0.09%$319.01+1.64%
U.S. Micro Cap Portfolio ETFDFMC273.12万0.04%75.58億 USD0.43%$57.813+0.20%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOVanguard Health Care ETFVHTU.S. Micro Cap Portfolio ETFDFMCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
